The Patient Assistance solutions ensure patients receive their medications, even if alternative funding is unavailable or they don’t qualify for need-based assistance.
The Sandoz investment is expected to be at least $400 million, supporting the company’s ambition to drive the future growth of its global biosimilars portfolio.